MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why DSGN Stock slipped -0.18% Today — RQD Quant Desk Flash
$11.06 -0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $11.04
Design Therapeutics Inc. (DSGN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $692.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $11.04 (-0.22%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DSGN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY DSGN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)
FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 42.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$11.65-11.5% Next Q
53
Q2 (-2Q)Grade C-$10.31-0.7% Next Q
50
Q3 (-1Q)Grade D$10.24+8% Next Q
48
CurrentGrade D$11.06-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DSGN Turnaround Squeeze
While DSGN currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.66) and Max Pain ($11.61) forces dealer call-delta covering toward $18.11.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DSGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DSGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DSGN Stock slipped -0.18% Today — RQD Quant Desk Flash
Design Therapeutics Inc. (DSGN) slipped -0.18% to $11.06, trading at 44% of its 52-week range ($6.16 – $17.25). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 44% of its 52-week range ($6.16 – $17.25) with RSI-14 at 42.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $11.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live DSGN Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DSGN)
- ✓Walkthrough of DSGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DSGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.68%📐 HORIZONTAL RANGE
2026-10-30O $10.96H $11.17L $10.51C $11.06VOL 249.5K
RES: $16.53SUP: $9.08SMA50: $12.66SMA200: $12.17
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DSGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DSGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DSGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DSGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DSGN)
Health Care Rank #477 of 1016
⚔️ GYRE vs DSGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DSGN vs. GYRE, WVE, APMD, ANL)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Design Therapeutics Inc. (DSGN) ranks #477 by composite RQD confidence (45/100, grade D) and #401 by equity capitalization ($692.2M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with DSGN at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DSGN
ACTIVE
Design Therapeutics Inc. | D | 45/100 | — | — | -32.1% | -0.18% | $692.2M | Benchmark Subject |
| GYRE Gyre Therapeutics Inc. | D | 46/100 | 72.3x | 95.4% | 25.4% | -9.59% | $714.8M | /gyre-vs-dsgn → |
| WVE Wave Life Sciences Inc. | E | 32/100 | — | — | -35.0% | -0.28% | $715.9M | /wve-vs-dsgn → |
| APMD Apnimed Inc. | D | 47/100 | — | — | — | -9.45% | $721.9M | /apmd-vs-dsgn → |
| ANL Adlai Nortye Group Ltd. | D+ | 52/100 | — | — | — | +0.78% | $662.0M | /anl-vs-dsgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001807120In its most recent audited fiscal period (FY2025, filed 2025-12-31), Design Therapeutics Inc. (DSGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.8M, operating cash flow of -$54.4M, and free cash flow of -$54.6M (-25.6% YoY). On the balance sheet, DSGN closed FY2025 with $226.2M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$69.8M | -$54.4M | -$54.6M | $226.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$49.6M | -$43.1M | -$43.4M | $252.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$66.9M | -$58.6M | -$58.6M | — | — |
3. DSGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DSGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Design Therapeutics Inc. (NASDAQ: DSGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $11.06 (-0.18% 1D, market cap $692.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DSGN ranks #477 in composite RQD confidence.
How does DSGN compare to GYRE and WVE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DSGN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D grade (46/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M) and WVE (Wave Life Sciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DSGN?
Per DSGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001807120), Design Therapeutics Inc. generated $0 in revenue, -$69.8M in net income, and -$54.6M in free cash flow against $226.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DSGN trading relative to its 50-day, 200-day, and 52-week technical levels?
DSGN last traded at $11.06 (-0.18% on volume of 276,616 shares), positioning the stock -12.64% below its 50-day simple moving average ($12.66) and -9.12% below its 200-day simple moving average ($12.17). Across its 52-week range of $6.16 to $17.25, DSGN sits at the 44.2% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.68 to $12.44).
DSGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DSGN stock moving today?
Why DSGN Stock slipped -0.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.